AQST

About AQST

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The Company has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place. Its active programs in its complex molecule pipeline portfolio are: AQST-109-SF and AQST-108-SF. AQST-109-SF (sublingual film) is an orally delivered epinephrine product candidate. AQST-108 is composed of the prodrug dipivefrin which is enzymatically cleaved into epinephrine after administration. Its CNS product candidate, Libervant, is an administered soluble film formulation of diazepam and is its advanced proprietary investigational product candidate. Its licensed products include Suboxone, Exservan, and KYNMOBI.